



(22) Date de dépôt/Filing Date: 2010/10/29

(41) Mise à la disp. pub./Open to Public Insp.: 2011/05/05

(45) Date de délivrance/Issue Date: 2020/06/30

(62) Demande originale/Original Application: 2 779 162

(30) Priorité/Priority: 2009/10/29 (US61/256,106)

(51) Cl.Int./Int.Cl. *A61K 31/683* (2006.01),
A61K 35/612 (2015.01)

(72) Inventeurs/Inventors:
SAMPALIS, FOTINI, CA;
HARLAND, HENRI, CA

(73) Propriétaire/Owner:
ACASTI PHARMA, INC., CA

(74) Agent: NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : COMPOSITIONS DE PHOSPHOLIPIDES THERAPEUTIQUES CONCENTREES

(54) Title: CONCENTRATED THERAPEUTIC PHOSHOLIPID COMPOSITIONS

(57) Abrégé/Abstract:

The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease metabolic syndrome, inflammation and diseases associated therewith neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.

Abstract

The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease metabolic syndrome, inflammation and diseases associated therewith neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.

5 CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONSCROSS-REFERENCE TO RELATED APPLICATIONSFIELD OF THE INVENTION

[0002] The invention relates to concentrated therapeutic compositions. More particularly, the invention relates to concentrated therapeutic phospholipid compositions useful for treating or preventing diseases.

15 BACKGROUND OF THE INVENTION

[0003] Genetic traits, coupled with a Western diet and lifestyle, have made cardiometabolic disorders ¹ metabolic syndrome (MetS) a growing global epidemic. Cardiometabolic syndrome refers to a cluster of cardiovascular risk factors that include central obesity, high blood pressure, impaired glucose tolerance, hyperglycemia and
20 dyslipidemia. Dyslipidemia is a major modifiable risk factor leading to atherosclerotic and related cardiovascular diseases (CVD), the nation's number one killer.

Cardiovascular Disease

[0004] Cardiovascular disease affects one in three people in the United States during their lifetime, and accounts for nearly a third of the deaths that occur each year (Rosamond W, *et al.*, *Circulation*, 115, e69-e171, (2007)). Cardiovascular diseases are defined as diseases
25 which affect the heart or blood vessels

[0005] Statins are considered as first-line therapy for subjects at risk for CVD focusing predominantly on the reduction in low-density lipoprotein cholesterol (LDL-C or "bad cholesterol"), to recommended target levels. However statins have minimal effect in raising
30 high-density lipoprotein cholesterol (HDL C or "good cholesterol"), now recognized as a major risk factor for developing cardiovascular disease. Treatment options to raise HDL-C are very limited and include Niaspan® (branded niacin) which is known to cause flushing

- 5 and is reported to cause hepatic enzyme abnormalities, and Tricor® (branded fenofibrates) which causes a 40% increase in LDL C and significant increase in liver enzymes, hematological changes, gall stones, pancreatitis, as well as myopathy. Some treatment options lower plasma triglycerides but have a negligible effect on HDL-C (Lovaza®). Other treatment options increase HDL-C, but are less effective on triglycerides.
- 10 [0006] Others have tried to increase HDL C (good cholesterol) without deleteriously affecting LDL, TG, or causing hypertension, but have not been successful. For example, torcetrapib appeared to raise HDL levels, but had no effect on TGs and LDL. However, torcetrapib caused severe hypertension and high mortality in phase III trials. Despite advancements in lowering total cholesterol, lipid abnormalities as well as other severe
- 15 negative side effects still prevail. Treatment gaps in the management of dyslipidemia, considered one of the top five major modifiable risk factors of CVD, represent critical unmet medical needs. While most treatment methods only target the intrinsic LDL-C synthesis in the liver, other treatments are needed to further reduce triglycerides while increasing HDL-C and not increasing LDL-C.
- 20 *Neurodevelopmental and neurodegenerative disease*
- [0007] Neurodevelopmental and neurodegenerative diseases/disorders and neurological imbalance (in neurotransmitters) affect many people, and are defined as chronic progressive neuropathy characterized by selective and generally symmetrical loss of neurons in motor, sensory, or cognitive systems. One progressive neurodegenerative disorder, Alzheimer's
- 25 disease (AD), is irreversible, and is characterized by gradual cognitive deterioration, changes in behavior and personality. These symptoms are related to neurochemical changes, neural death, and the breakdown of the inter-neural connections. Loss of short-term memory is often the first sign, followed by cognitive deficits involving multiple functions. Early stages of AD and mild cognitive impairment are characterized as milder forms of memory loss or
- 30 cognitive impairment that could precede the onset of dementia and AD. Prevention of further cognitive decline in subjects with these possible precursor conditions is of paramount importance given that reversibility of AD is not possible.
- [0008] It is estimated there are currently about 5.1 million people with Alzheimer's disease (AD) in the United States (Alzheimer's Association, 2007) and this number is
- 35 expected to reach 13.2 million by 2050 (Hebert et al., 2003). Alzheimer's is ranked as the 7th leading cause of death in the US for people of all ages and the 5th for people aged 65 or older

- 5 (National Center for Health Statistics, 2004). In Canada it is 280,000 people over 65 that are estimated to have AD, and over 750,000 are expected to have the disease by 2031 (Alzheimer Society of Canada, 2006). It is estimated to 10% of all North Americans over the age of 70 years have early stage AD or mild cognitive impairment.

- [0009] Alzheimer's disease is characterized by two main pathological features of the
10 brain; intracellular neurofibrillary tangles formed by abnormal protein τ (tau); and extracellular neuritic plaques formed by β -amyloid peptides ($A\beta$) (Kuo et al., 1996). The overproduction of $A\beta$ 42 is genetically induced but environmental risk factors are required to get fully symptomatic AD (Grant et al., 2002). Among these risk factors, low docosahexaenoic acid (DHA) is one of the most important dietary risk factor for AD (Morris
15 et al., 2005). The reasons for the impact of DHA on learning and memory and the association with AD are unclear but could result from its loss in synapses (Montine et al., 2004), which are normally rich in DHA (Salem et al., 2001), where it is particularly important for postsynaptic transmission and neuroprotection (Bazan, 2003). Studies in animal models have consistently showed that brain n-3 fatty acid content is highly dependent on dietary intake
20 and aging (Favrre et al., 2000; Youdim et al., 2000; Calon & Cole, 2007). However, some reports claim higher concentrations of DHA have a deleterious effect in neurological patients.

Omega-3 Fatty Acids and Inflammation

- [0010] Several animal studies, has shown that increased DHA intake has been found to increase hippocampal acetylcholine levels and its derivatives, neuroprotectin D1, which
25 decreased cell death (Aid et al, 2005; Lukiw et al., 2005). A study conducted on aged mice showed that DHA intake improved memory performance (Lim et al. 2001). In another Alzheimer's disease mouse model, reduction in dietary DHA showed loss of postsynaptic proteins associated with increased oxidation, which was localized in the dendrites. However, when a group of DHA-restricted mice were given DHA, they showed signs that the DHA
30 intake protected them against dendritic pathology, implying that DHA could be useful in preventing cognitive impairment in Alzheimer's Disease (Calon et al., 2004).

- [0011] Several epidemiological studies have shown a protective effect associated with increased fish intake (a direct source of omega 3 fatty acids) against dementia and cognitive impairment decline (Kalmijin et al. 1997, Barberger-Gateau et al. 2002; Morris et al 2003).
35 Recently, one large randomized double-blind placebo-controlled study found 1.6 g DHA and 0.7 EPA may be beneficial in reducing risk for AD (Freund-Levi et al, 2006). In addition,

- 5 there is mounting evidence that dietary supplementation with Omega 3 fatty acids may be beneficial in different psychiatric conditions such as mood behaviour, depression and dementia (Bourre et al., 2005; Peet and Stokes, 2005; Stoll et al., 1999).

[0012] The anti-inflammatory effects of omega-3 fatty acids have been widely studied with positive results for several chronic inflammatory diseases. C-reactive protein (CRP) is a
10 protein that increases dramatically during inflammatory processes and is commonly measured as a marker of inflammation. Greater intake of omega-3 polyunsaturated fatty acid is related to a lower prevalence of elevated CRP levels. Animal models of colitis indicate that fish oil, a natural source of omega 3 fatty acids, decreases colonic damage and inflammation. Fish oil supplements in subjects with IBD have shown to modulate levels of inflammatory mediators
15 and may be beneficial for the induction and maintenance of remission in ulcerative colitis. In the management of RA and other inflammatory conditions, side effects limit the use of NSAIDs, such as salicylates, ibuprofen and naproxen. A clinical trial showed that 39 percent of subjects with RA supplemented with cod liver oil were able to reduce their daily NSAID requirement by greater than 30 percent. Omega-3 fatty acids have been used to reduce the
20 risk for sudden death caused by cardiac arrhythmias.

[0013] Furthermore, omega-3 fatty acids have been shown to improve insulin sensitivity and glucose tolerance in normoglycemic men and in obese individuals. Omega-3 fatty acids have also been shown to improve insulin resistance in obese and non-obese subjects with an inflammatory phenotype. Lipid, glucose and insulin metabolism have been show to be
25 improved in overweight hypertensive subjects through treatment with omega-3 fatty acids.

[0014] Omega-3 fatty acids can be obtained from marine organisms such as squid, fish, krill, etc. and are sold as dietary supplements. However, the uptake of omega-3 fatty acids by the body is not efficient and these raw oils contain other substances such a triglycerides and cholesterol which are known to cause deleterious side effects such as an increase in LDL-C.
30 Certain fish oils have been developed as pharmaceutical-grade OM3-acid ethyl esters. One such OM3-acid ethyl ester is presently sold under the brand name Lovaza®. Studies have shown that Lovaza® can decrease plasma triglycerides levels in patients, however, Lovaza® has a negligible effect on raising good cholesterol (HDL-C). AMR101 is another ethyl ester

- 5 form of OM3 fatty acids based on EPA with little or no DHA that is presently in clinical trials. AMR101 also appears to decrease triglycerides but also has a negligible effect on raising HDL-C.

[0015] A phospholipid composition of OM3 fatty acids has been disclosed in US 2004/0234587. This phospholipid composition has OM3 fatty acids esterified to the
10 phospholipid. This phospholipid composition is reported to be at a concentration of about 40% phospholipids (w/w composition) and contains high concentrations of triglycerides (about 45%) and free fatty acids (about 15%). When tested in subjects, this composition demonstrated very little effect on lowering triglyceride plasma levels (less than 11% reduction).

- 15 [0016] Marine oil compositions comprising free fatty acids and lipids, including OM3 fatty acids and phospholipids, have been disclosed in WO 2000/23546, however the compositions do not disclose OM3 fatty acids esterified to diglycerol phosphate and have very high concentrations of triglycerides and free fatty acids, and for these reasons would not be expected to reduce triglycerides even to the level of the composition disclosed in US
20 2004/0234587, described above.


[0017] Therefore, new forms of omega-3 fatty acids are needed that are useful for treating or preventing disease. Described herein are novel concentrated therapeutic phospholipid compositions, as well as pharmaceutical compositions comprising same, and methods of their use.

25

5

SUMMARY OF THE INVENTION

[0018] Accordingly, in one aspect concentrated therapeutic phospholipid compositions are described, the compositions comprising compounds of the Formula I:



10

(I)


wherein for each compound of Formula I in the compositions

each R_1 is independently selected from hydrogen or any fatty acid;

each R_2 is independently selected from hydrogen or any fatty acid;

wherein at least one of R_1 and R_2 in each compound of Formula I is a fatty acid; and

15 each X is independently selected from $-\text{CH}_2\text{CH}_2\text{NH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ or



20 wherein the total amount of the compounds of Formula I in the composition being at a concentration of between 45% (w/w) to about 99% (w/w).

- 5 [0019] In some embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 45% (w/w (phospholipids/total composition)) up to 70% (w/w (phospholipids/total composition)). In still further embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 50% (w/w (phospholipids/total composition)) up to 70% (w/w (phospholipids/total composition)).
- 10 In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 60% (w/w (phospholipid/total composition)) up to 70% (w/w (phospholipids/total composition)). In still other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of about 66% (w/w (phospholipids/total composition)).
- 15

- [0020] In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of above 70% (w/w (phospholipids/total composition)) to about 99% (w/w (phospholipids/total composition)). In still other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 80% (w/w (phospholipids/total composition)) to about 98% (w/w (phospholipids/total composition)). In still other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of between about 85% (w/w (phospholipids/total composition)) to about 95% (w/w (phospholipids/total composition)). In
- 20 further embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition are in a concentration of about 90% (w/w (phospholipids/total composition)).
- 25

- [0021] In some embodiments, R1 is a monounsaturated fatty acid. In other embodiments, R1 is a polyunsaturated fatty acid. In some embodiments, R2 is a monounsaturated fatty acid. In other embodiments, R2 is a polyunsaturated fatty acid. In other embodiments, the polyunsaturated fatty acid is an omega 3 fatty acid. In still other embodiments, both R1 and R2 are each independently selected from an omega 3 fatty acid. When at least one of R1 and R2 is an omega 3 fatty acid, the concentrated therapeutic phospholipid composition comprising compounds of Formula I is known as an OM3:PL.
- 30

35

- 5 [0022] In other embodiments, R1 is docosahexaenoic acid (DHA). In other embodiments, R2 is a monounsaturated fatty acid and R1 is DHA. In other embodiments, R2 is a polyunsaturated fatty acid and R1 is DHA. In other embodiments, R2 is an omega 3 fatty acid and R1 is DHA. In still further embodiments, R2 is EPA and R1 is DHA. In still further embodiments, R2 is DHA and R1 is DHA.
- 10 [0023] In other embodiments, R1 is eicosapentaenoic acid (EPA). In other embodiments, R2 is a monounsaturated fatty acid and R1 is EPA. In other embodiments, R2 is a polyunsaturated fatty acid and R1 is EPA. In other embodiments, R2 is an omega 3 fatty acid and R1 is EPA. In still further embodiments, R2 is DHA and R1 is EPA. In still further embodiments, R2 is EPA and R1 is EPA.
- 15 [0024] In another embodiment, R2 is DHA. In other embodiments, R1 is a monounsaturated fatty acid and R2 is DHA. In other embodiments, R1 is a polyunsaturated fatty acid and R2 is DHA. In other embodiments, R1 is an omega 3 fatty acid and R2 is DHA.
- [0025] In other embodiments, R2 is EPA. In other embodiments, R1 is a monounsaturated fatty acid and R2 is EPA. In other embodiments, R1 is a polyunsaturated fatty acid and R2 is EPA. In other embodiments, R1 is an omega 3 fatty acid and R2 is EPA.
- 20 [0026] In some embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have predominantly DHA at the R2 position of Formula I. In other embodiments, there is more DHA in the compounds of Formula I in the concentrated therapeutic phospholipid composition than EPA. In some embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 60% DHA. In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 70% DHA. In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 80% DHA. In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 90% DHA. In other embodiments, the compounds of Formula I in the concentrated therapeutic phospholipid composition have greater than 95% DHA.
- 25
- 30

5 [0027] In some embodiments, there are free fatty acids in the concentrated therapeutic phospholipid composition, in addition to the fatty acids esterified to the phosphate. In other embodiments, there are essentially no free fatty acids (also expressed as 0% free fatty acids (or FFA)) in the concentrated therapeutic phospholipid composition.

[0028] In other embodiments, the ratio of the total amount of DHA to EPA in the
10 concentrated therapeutic phospholipid composition is between about 1:1 and 1:0.1. In some embodiments, the ratio is between about 1:0.7 and about 1:0.3. In other embodiments, the ratio is about 1:0.5.


[0029] In some embodiments, the ratio of the total amount of EPA to DHA in the compounds of Formula I in the concentrated therapeutic phospholipid composition is
15 between about 1:1 and 1:0.1. In some embodiments, the ratio is between about 1:0.7 and about 1:0.3. In other embodiments, the ratio is about 1:0.5.

[0030] In some embodiments, the total amount of OM3 fatty acids in the concentrated therapeutic phospholipid composition is between about 20% and about 50%. In other
20 embodiments, the total amount of OM3 fatty acids in the concentrated therapeutic phospholipid composition is between about 30% and about 45%. In other embodiments, the total amount of OM3 fatty acids in the concentrated therapeutic phospholipid composition is about 40%.

[0031] In some embodiments, the total amount of DHA in the concentrated therapeutic phospholipid composition is between about 5% and 20%. In some embodiments, the total
25 amount of DHA in the concentrated therapeutic phospholipid composition is between about 10% and 15%. In some embodiments, the total amount of DHA in the concentrated therapeutic phospholipid composition is about 14%.


[0032] In some embodiments, the total amount of EPA in the concentrated therapeutic phospholipid composition is between about 10% and 30%. In some embodiments, the total
30 amount of DHA in the concentrated therapeutic phospholipid composition is between about 15% and 25%. In some embodiments, the total amount of EPA in the concentrated therapeutic phospholipid composition is about 22%.

- 5 [0033] In some embodiments, X is $-\text{CH}_2\text{CH}_2\text{NH}_3$. In other embodiments, X is $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$. In some embodiments, X is



- [0034] In some embodiments, the concentrated therapeutic phospholipid composition
10 comprises predominantly phospholipids containing $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ (also known as a phosphoydyl-N-trimethylethanolamine).

- [0035] In other embodiments, the concentrated therapeutic phospholipid composition further comprises an antioxidant. In some embodiments, the antioxidant is a carotenoid. In other embodiments, the carotenoid is pro-vitamin A. In other embodiments, the antioxidant
15 is a flavonoid. In other embodiments, the flavonoid is selected from naringin, naringenin, hesperetin/kaempferol, rutin, luteolin, neohesperidin, quercetin. In other embodiments, the flavonoid is



- 20 [0036] In some embodiments, the concentration of the flavonoid is between about 1 mg/kg (w/w of composition) and about 20 mg/kg (w/w of composition). In other embodiments, the concentration of the flavonoid is greater than about 10 mg/kg (w/w of composition).

5 [0037] In further embodiments, the concentrated therapeutic phospholipid composition has a concentration of astaxanthin greater than 2000 mg/kg (w/w of composition). In still other embodiments, the concentration of astaxanthin is between about 2,000 mg/kg (w/w of composition) and about 5,500 mg/kg (w/w of composition).

[0038] In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below about 22% (w/w of composition). In some
10 embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below about 15% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below about 10% (w/w of composition). In some embodiments, the concentrated therapeutic
15 phospholipid composition has a free fatty acid concentration below about 5% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration of about 1% (w/w of composition). In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration below 1% (w/w of composition). In some embodiments, the concentrated therapeutic
20 phospholipid composition has a free fatty acid concentration of 0% (w/w of composition).

[0039] In some embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration of between about 1% (w/w) and about 20% (w/w). In some
embodiments, the concentrated therapeutic phospholipid composition has a free fatty acid concentration of between about 5% (w/w) and about 17% (w/w). In some embodiments, the
25 concentrated therapeutic phospholipid composition has a free fatty acid concentration of between about 10% (w/w) and about 15% (w/w).

[0040] In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration between about 0% (w/w) and about 30% (w/w). In other
embodiments, the concentrated therapeutic phospholipid composition has a triglyceride
30 concentration between about 5% and about 20%. In still further embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration between about 10% and about 15%.

5 [0041] In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration below about 15%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration below about 10%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration below about 5%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration about 1%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration below 1%. In some embodiments, the concentrated therapeutic phospholipid composition has a triglyceride concentration of about 0%.

[0042] In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 50% compounds of Formula I (w/w), wherein at least 15% of the fatty acid content is EPA, at least 9 % of the fatty acid content is DHA, and at least 0.1% astaxanthin (w/w). In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 66% compounds of Formula I (w/w), wherein at least 20% of the fatty acid content is EPA, at least 12 % of the fatty acid content is DHA, and at least 0.4% astaxanthin (w/w). In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 90% compounds of Formula I (w/w) , at least 22% of the fatty acid content is EPA, at least 12% of the fatty acid content is DHA, and 0.4% astaxanthin (w/w).

[0043] In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 50% compounds of Formula I (w/w composition), wherein at least 15% of the fatty acid content is EPA, at least 9 % of the fatty acid content is DHA. In other embodiments, the concentrated therapeutic phospholipid composition comprises at least 66% compounds of Formula I (w/w), wherein at least 20% of the fatty acid content is EPA, at least 12 % of the fatty acid content is DHA. In other embodiments, the concentrated therapeutic phospholipid composition comprises above 70% compounds of Formula I(w/w), wherein at least 22% of the fatty acid content is EPA, at least 12% of the fatty acid content is DHA. In other embodiments, the concentrated therapeutic phospholipid composition comprises above 90% compounds of Formula I(w/w), wherein at least 22% of the fatty acid content is EPA, at least 12% of the fatty acid content is DHA.

5 [0044] In one aspect, a concentrated therapeutic phospholipid composition is described comprising compounds of Formula at a concentration of about 66% (w/w (phospholipids/total composition) a free fatty acid (FFA) concentration of less than 6% (w/w FFA/total composition) and a triglyceride concentration of about 0%, the composition being useful for treating and preventing cardiometabolic disorders / metabolic syndrome. In some
10 embodiments, 1 g of the concentrated therapeutic phospholipid composition comprises about 387 mg of total OM3 fatty acids wherein EPA is at about 215 mg and DHA is at about 136 mg) and astaxanthine at about 5 mg.

[0045] In one aspect, a concentrated therapeutic phospholipid composition is described comprising compounds of Formula at a concentration of above 70% (w/w
15 (phospholipids/total composition), a free fatty acid (FFA) concentration of about 0% and a triglyceride concentration of about 0%, the composition being useful for treating and preventing neurodegenerative and neurodevelopmental disorders and diseases.

[0046] In one aspect, the invention is based in part on the unexpected and surprising discovery that concentrated therapeutic phospholipid compositions are useful in modulating
20 plasma triglyceride levels as well as plasma HDL C levels, while not elevating LDL C levels. This unexpected and surprising discovery is useful in the treatment or prevention of disorders associated with increased triglyceride levels, increased LDL-C levels and decreased HDL-C levels. Such diseases and disorders include but are not limited to cardiometabolic disorders / metabolic syndrome (MetS), neurodevelopmental and neurodegenerative diseases/disorders,
25 and inflammation disorders.


[0047] In another aspect, a method of treating or preventing a cardiometabolic disorder / metabolic syndrome is described, the method comprising administering to a subject in need thereof a concentrated therapeutic phospholipid composition. In some embodiments, the cardiometabolic disorder is selected from atherosclerosis, arteriosclerosis, coronary heart
30 (carotid artery) disease (CHD or CAD), acute coronary syndrome (or ACS), valvular heart disease, aortic and mitral valve disorders, arrhythmia / atrial fibrillation, cardiomyopathy and heart failure, angina pectoris, acute myocardial infarction (or AMI), hypertension, orthostatic hypotension, shock, embolism (pulmonary and venous), endocarditis, diseases of arteries, the aorta and its branches, disorders of the peripheral vascular system (peripheral arterial disease
35 or PAD), Kawasaki disease, congenital heart disease (cardiovascular defects) and stroke (cerebrovascular disease), dyslipidemia, hypertriglyceridemia, hypertension, heart failure,

- 5 cardiac arrhythmias, low HDL levels, high LDL levels, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia, stroke, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, omega-3 deficiency, phospholipid
- 10 deficiency, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, acute coronary syndrome (ACS), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), arterial occlusive diseases, cerebral atherosclerosis, arteriosclerosis, cerebrovascular disorders, myocardial ischemia, coagulopathies leading to thrombus formation in a vessel and diabetic autonomic neuropathy.
- 15 In some instances, the methods described above for treating or preventing a cardiometabolic disorder / metabolic syndrome may utilize concentrated therapeutic phospholipid compositions having a concentration of 66% (w/w (phospholipids/composition)).


- [0048] In another aspect, methods of treating, preventing, or improving cognition and /or a cognitive disease, disorder or impairment (memory, concentration, learning (deficit)), or of
- 20 treating or preventing neurodegenerative disorders are described, the method comprising administering to a subject in need thereof a concentrated therapeutic phospholipid composition. In some embodiments, the cognitive disease, disorder or impairment is selected from Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), autism/autism spectrum disorder (ASD), (dyslexia, age-associated memory impairment and
- 25 learning disorders, amnesia, mild cognitive impairment, cognitively impaired non-demented, pre-Alzheimer's disease, Alzheimer's disease, epilepsy, Pick's disease, Huntington's disease, Parkinson disease, Lou Gehrig's disease, pre-dementia syndrome, Lewy body dementia dementia, dentatorubropallidolusian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia, amyotrophic lateral sclerosis, familial spastic
- 30 paraparesis, spinal muscular atrophy, spinal and bulbar muscular atrophy, age-related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, conditions that influence the intensity of brain waves and/or brain glucose utilization, stress, anxiety, concentration and attention impairment, mood deterioration, general cognitive and mental well being, neurodevelopmental,
- 35 neurodegenerative disorders, hormonal disorders, neurological imbalance or any combinations thereof. In a specific embodiment, the cognitive disorder is memory impairment. In some instances, the methods described above for treating, preventing, or

- 5 improving cognition and /or a cognitive disease, disorder or impairment (memory, concentration, learning (deficit)), or of treating or preventing neurodegenerative disorders may utilize concentrated therapeutic phospholipid compositions having a concentration of greater than 70% (w/w (phospholipids/composition)).
- [0049] In another aspect, a method for inhibiting, preventing, or treating inflammation or
10 an inflammatory disease is described, the method comprising administering to a subject in need thereof, a concentrated therapeutic phospholipid composition. In some embodiments, the inflammation or inflammatory disease is selected from organ transplant rejection; reoxygenation injury resulting from organ transplantation (see Grupp *et al.*, J. Mol. Cell Cardiol. 31: 297-303 (1999)) including, but not limited to, transplantation of the following
15 organs: heart, lung, liver and kidney; chronic inflammatory diseases of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases (IBD) such as ileitis, ulcerative colitis (UC), Barrett's syndrome, and Crohn's disease (CD); inflammatory lung diseases such as asthma, acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease
20 (COPD); inflammatory diseases of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory diseases of the gum, including gingivitis and periodontitis; inflammatory diseases of the kidney including uremic complications, glomerulonephritis and nephrosis; inflammatory diseases of the skin including sclerodermatitis, psoriasis and eczema; inflammatory diseases
25 of the central nervous system, including chronic demyelinating diseases of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, Epilepsy, amyotrophic lateral sclerosis and viral or autoimmune encephalitis, preeclampsia; chronic liver failure, brain and spinal cord trauma, and cancer. The inflammatory disease can
30 also be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to proinflammatory cytokines, *e.g.*, shock associated with proinflammatory cytokines. Such shock can be induced, *e.g.*, by a chemotherapeutic agent that is administered as a treatment for cancer. Other disorders include depression, obesity, allergic diseases, acute
35 cardiovascular events, muscle wasting diseases, and cancer cachexia. Also inflammation that results from surgery and trauma can be treated with the concentrated therapeutic phospholipid compositions.

[0049a] In one aspect, it is provided a concentrated therapeutic phospholipid composition comprising compounds of the Formula I:




wherein R_1 and R_2 each independently represent a docosahexaenoic acid (DHA) or an eicosapentaenoic acid (EPA) residue; and wherein each X is independently selected from $-\text{CH}_2\text{CH}_2\text{NH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ and




free EPA and free DHA, wherein the total free and bound EPA in the extract is at a concentration of between 15% and 25% (w/w), and the total free and bound DHA in the extract is at a concentration of between 10% and 15% (w/w), wherein the total phospholipids in the composition are at a concentration of 50% (w/w (phospholipids/composition)) to $55\% \pm 5\%$ (w/w (phospholipids/composition)).

[0049b] It is further provided a concentrated therapeutic phospholipid composition for reducing triglycerides level comprising compounds of the Formula I:



wherein R_1 and R_2 each independently represent a docosahexaenoic acid (DHA) or an eicosapentaenoic acid (EPA) residue; and each X is independently selected from $-\text{CH}_2\text{CH}_2\text{NH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ and



wherein the total phospholipids in the composition are at a concentration of 50% (w/w (phospholipids/composition)) to 55% $\pm$ 5% (w/w (phospholipids/composition)).

5 [0050] The details of the invention are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular
10 forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

DESCRIPTION OF THE FIGURES

15 [0051] FIG. 1A depicts a flow chart for the process for making the concentrated therapeutic phospholipid compositions.
[0052] FIG. 1B depicts a flow chart for the process for making the concentrated therapeutic phospholipid compositions.
[0053] FIG. 1C depicts shows the schematic of the supercritical CO₂ extraction
20 apparatus.
[0054] FIG. 2 depicts circulating plasma triglyceride concentration of C57BL/6 mice treated with Composition 3.
[0055] FIG. 3 depicts circulating plasma HDL-Cholesterol concentration of C57BL/6 mice treated with Composition 3.
25 [0056] FIG. 4 depicts circulating plasma percentage of HDL-Cholesterol in C57BL/6 mice treated with Composition 3.
[0057] FIG. 5 depicts circulating plasma LDL-Cholesterol concentration of C57BL/6 mice treated with Composition 3.
[0058] FIG. 6 depicts circulating plasma percentage of LDL-Cholesterol in C57BL/6
30 mice treated with Composition 3.
[0059] FIG. 7 depicts circulating plasma NEFA concentration of C57BL/6 mice treated with Composition 3.
[0060] FIG. 8 depicts circulating plasma Glucose concentration of C57BL/6 mice treated with Composition 3.
35 [0061] FIG. 9 depicts circulating plasma Phospholipid concentration of C57BL/6 mice treated with Composition 3.

- 5 [0062] FIG. 10 depicts circulating plasma ALT concentration of C57BL/6 mice treated with Composition 3.
- [0063] FIG. 11 depicts liver Total Cholesterol concentration of C57BL/6 mice treated with Composition 3.
- [0064] FIG. 12 depicts liver Triglyceride concentration of C57BL/6 mice treated with
- 10 Composition 3.
- [0065] FIG. 13 depicts circulating plasma triglyceride concentration of LDLr KO mice treated with Composition 3.
- [0066] FIG. 14 depicts circulating plasma HDL-Cholesterol concentration of LDLr KO mice treated with Composition 3.
- 15 [0067] FIG. 15 depicts circulating plasma percentage of HDL-Cholesterol in LDLr KO mice treated with Composition 3.
- [0068] FIG. 16 depicts liver Total Cholesterol concentration of LDLr KO mice treated with Composition 3.
- [0069] FIG. 17 depicts liver Triglyceride concentration of LDLr KO mice treated with
- 20 Composition 3.
- [0070] FIG. 18 depicts circulating plasma Triglyceride concentration of ApoA-1 CET Tg mice treated with Composition 3.
- [0071] FIG. 19 depicts circulating plasma total cholesterol concentration of adult male SD, ZDF, SHR and JCR:LA rats.
- 25 [0072] FIG. 20 depicts circulating plasma total cholesterol concentration of adult male SD, ZDF, SHR and JCR:LA rats.
- [0073] FIG. 21 depicts circulating plasma HDL/LDL concentration of adult male SD, ZDF, SHR and JCR:LA rats.
- [0074] FIG. 22 depicts circulating plasma total cholesterol/HDL concentration of adult
- 30 male SD, ZDF, SHR and JCR:LA rats.
- [0075] FIG. 23 depicts prothrombin time of adult male SD, ZDF, SHR and JCR:LA rats.
- [0076] FIG. 24 depicts OGTT area under the curve data in ZDF male rats treated with Composition 3 for 28 days.
- [0077] FIG. 25 depicts OGTT area under the curve data in ZDF male rats treated with
- 35 Composition 3 for 28 days.
- [0078] FIG. 26 depicts OGTT area under the curve data in SD male rats treated with Composition 3 for 28 days.

- 5 [0079] FIG. 27 depicts OGTT area under the curve data in ZDF male rats treated with Composition 3 for 28 days.
- [0080] FIG. 28 depicts the effects of Composition 3 on plasma total cholesterol in male ZDF rats compared to age-matched controls.
- [0081] FIG. 29 depicts the effects of Composition 3 on plasma HDL-cholesterol in male
10 ZDF rats compared to age-matched controls.
- [0082] FIG. 30 depicts the effects of Composition 3 on plasma triglycerides in male ZDF rats compared to age-matched controls.
- [0083] FIG. 31 depicts the effects of Composition 3 on glucose intolerance in male ZDF rats.
- 15 [0084] FIG. 32 depicts the effects of Composition 3 on glucose intolerance in male ZDF rats.
- [0085] FIG. 33 depicts the effects of Composition 3 on glucose intolerance in male SD rats.
- [0086] FIG. 34 depicts the effects of Composition 3 on glucose intolerance in male SD
20 rats.
- [0087] FIG. 35 depicts the comparative effects of Composition 3 and Lovaza^(R) on the Omega-3 Index.

DETAILED DESCRIPTION OF THE INVENTION

- [0088] It has been unexpectedly discovered that concentrated therapeutic phospholipid
25 compositions demonstrate surprising effects in the treatment of metabolic disorders, cardiovascular disease, neurodevelopmental disorders and neurodegenerative diseases, and inflammation disorders.

DEFINITIONS

- [0089] The following definitions are used in connection with the concentrated therapeutic
30 phospholipid compositions:
- [0090] The term "concentrated therapeutic phospholipid composition" and "concentrated therapeutic phospholipid compositions" as used herein refer to the concentrated therapeutic phospholipid compositions comprising compounds of Formula I.

5 [0091] The articles “a” and “an” are used in this disclosure to refer to one or more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0092] The term “and/or” is used in this disclosure to mean either “and” or “or” unless indicated otherwise.

10 [0093] The term “about” when used in this disclosure along with a recited value means the value recited and includes the range of + or – 5 % of the value. For example, the phrase about 80% means 80% and + or – 5% of 80, *i.e.* 76% to 84%. The recited value “about 0%” as used herein means that the detectable amount is less than one part per thousand.

[0094] The term “fatty acid” or “fatty acid residue” as used herein means a carboxylic acid with a long unbranched aliphatic chain, which is either saturated or unsaturated. Saturated fatty acids have the general formula $C_nH_{2n+1}COOH$. Examples of saturated fatty acids include but are not limited to: Propanoic acid, Butanoic acid, Pentanoic acid, Hexanoic acid, Heptanoic acid, Octanoic acid, Nonanoic acid, Decanoic acid, Undecanoic acid, Dodecanoic acid, Tridecanoic acid, Tetradecanoic acid, Pentadecanoic acid, Hexadecanoic acid, Heptadecanoic acid, Octadecanoic acid, Nonadecanoic acid, Eicosanoic acid, Heneicosanoic acid, Docosanoic acid, Tricosanoic acid, Tetracosanoic acid, Pentacosanoic acid, Hexacosanoic acid, Heptacosanoic acid, Octacosanoic acid, Nonacosanoic acid, Triacontanoic acid, Henatriacontanoic acid, Dotriacontanoic acid, Tritriacontanoic acid, Tetratriacontanoic acid, Pentatriacontanoic acid, Hexatriacontanoic acid. An unsaturated fat is a fat or fatty acid in which there are one or more double bonds in the fatty acid chain. A fat molecule is monounsaturated if it contains one double bond, and polyunsaturated if it contains more than one double bond. Examples of unsaturated fatty acids include but are not limited to: Myristoleic acid, Palmitoleic acid, Sapienic acid, Oleic acid, Linoleic acid, α -Linolenic acid, Arachidonic acid, Eicosapentaenoic acid (EPA), Erucic acid, Docosahexaenoic acid (DHA), and Docosapentaenoic acid.

20
25
30

[0095] A “subject” is a mammal, *e.g.*, a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.

[0096] Representative “pharmaceutically acceptable salts” include, *e.g.*, water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2, 2 - disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulinate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine,

35

5 hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, 10 p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valcrate salts.

[0097] The term "metabolic disorder" as used herein refers to disorders, diseases and syndromes involving dyslipidemia, and the terms metabolic disorder, metabolic disease, and metabolic syndrome are used interchangeably herein.

15 [0098] An "effective amount" when used to describe an amount of a concentrated therapeutic phospholipid composition useful for treating or preventing a disease or disorder, is an amount that is efficacious with respect to the disease or disorder connected with that particular effective amount.

[0099] The term "carrier", as used in this disclosure, encompasses carriers, excipients, 20 and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body.

[0100] The term "treating", with regard to a subject, refers to improving at least one 25 symptom of the subject's disorder. Treating can be curing, improving, or at least partially ameliorating the disorder.

[0101] The term "disorder" is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.

[0102] The term "administer", "administering", or "administration" as used in this 30 disclosure refers to either directly administering a compound or pharmaceutically acceptable salt of the compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.

35

5 *Methods of Making the Concentrated Therapeutic Phospholipid Compositions*

[0103] The concentrated therapeutic phospholipid compositions can be made or produced by any method known to one of skill in the art. For example, phospholipid containing oils can be isolated from natural sources (see US 2004/0234587, US 2009/0074857, and US 2008/0274203),

10 which can then be further processed. Alternatively, following the process outlined in Figure 1a results in bulk raw material krill oil ready for further processing. These phospholipid containing oils can be further processed using countercurrent supercritical CO₂ extraction (Lucien, F. P., et al., *Australas Biotechnol.* 1993, 3, 143-147) to concentrate the compositions to produce the concentrated therapeutic phospholipid compositions described herein (see

15 Figure 1b). For example, countercurrent supercritical CO₂ extraction at 70 C and 30 MPa and with a CO₂/oil ratio of 72 can be used to remove certain biomolecules such as all triglycerides from the bulk raw material krill oil as well as some of the free fatty acids (Figure 1b). As more of the TGs and FFAs are removed from the bulk raw material krill oil, the concentration of the phospholipids increases. When the TGs have been removed through

20 this process the phospholipid composition is at about 66% concentration (w/w (phospholipids/composition)) and contains less than 5% free fatty acids (w/w). As more of the FFAs are removed using this process, a concentrated therapeutic phospholipid composition results having a phospholipid concentration above 70% up to about 90% (w/w (phospholipids/composition)) having about 1% or less TG and about 0% FFA. Other aquatic

25 and/or marine biomasses may be used as starting materials, such as, for example, squid or blue mussels. Additional components can be added before, during, or after processing. Alternatively, phospholipids can be synthesized; a typical way to synthesize would be, among others, according to the procedure described in US 7,034,168.

30 *Methods for using the Concentrated Therapeutic Phospholipid Compositions*

[0104] Described herein are methods of reducing circulating plasma concentrations of triglycerides, LDL-cholesterol, total cholesterol and NEFA, the method comprising administering to a subject in need thereof an effective amount of a Composition of the Invention.

35

- 5 [0105] Also provided are methods of increasing plasma concentrations of HDL-cholesterol and hepatic concentrations of triglycerides and total cholesterol, the method comprising administering to a subject in need thereof an effective amount of a concentrated therapeutic phospholipid composition.
- 10 [0106] In another aspect, a method of reducing TG without the risk of increasing LDL is described, the method comprising administering to a subject in need thereof, a concentrated therapeutic phospholipid composition.
- [0107] Also provided are methods for inhibiting, preventing, or treating a metabolic disorder, or symptoms of a metabolic disease, in a subject, the method comprising administering to a subject in need thereof an effective amount of a concentrated therapeutic phospholipid composition. Examples of such disorders include, but are not limited to atherosclerosis, dyslipidemia, hypertriglyceridemia, hypertension, heart failure, cardiac arrhythmias, low HDL levels, high LDL levels, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia, stroke, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, acute coronary syndrome (ACS), non-alcoholic fatty liver disease, arterial occlusive diseases, cerebral atherosclerosis, arteriosclerosis, cerebrovascular disorders, myocardial ischemia, and diabetic autonomic neuropathy.
- 20
- 25
- 30 [0108] Also provided are methods for inhibiting, preventing, or treating inflammation or an inflammatory disease in a subject. The inflammation can be associated with an inflammatory disease. Inflammatory diseases can arise where there is an inflammation of the body tissue. These include local inflammatory responses and systemic inflammation. Examples of such diseases include, but are not limited to: organ transplant rejection; reoxygenation injury resulting from organ transplantation (see Grupp *et al.*, J. Mol. Cell Cardiol. 31: 297-303 (1999)) including, but not limited to, transplantation of the following organs: heart, lung, liver and kidney; chronic inflammatory diseases of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases such as ileitis, ulcerative colitis, Barrett's syndrome,
- 35

5 and Crohn's disease; inflammatory lung diseases such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; inflammatory diseases of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory diseases of the gum, including gingivitis and periodontitis; inflammatory diseases of the kidney including uremic complications,
10 glomerulonephritis and nephrosis; inflammatory diseases of the skin including sclerodermitis, psoriasis and eczema; inflammatory diseases of the central nervous system, including chronic demyelinating diseases of the nervous system, multiple sclerosis, AIDS-related neurodegeneration and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and viral or
15 autoimmune encephalitis. Metabolic disease such as type II diabetes mellitus; the prevention of type I diabetes; dyslipidemia; diabetic complications, including, but not limited to glaucoma, retinopathy, nephropathy, such as microalbuminuria and progressive diabetic nephropathy, polyneuropathy, atherosclerotic coronary arterial disease, peripheral arterial disease, nonketotic hyperglycemic hyperosmolar coma, mononeuropathies, autonomic
20 neuropathy, joint problems, and a skin or mucous membrane complication, such as an infection, a shin spot, a candidal infection or necrobiosis lipoidica diabetorum; immune-complex vasculitis, systemic lupus erythematosus; inflammatory diseases of the heart such as cardiomyopathy, ischemic heart disease hypercholesterolemia, and atherosclerosis; as well as various other diseases that can have significant inflammatory components, including
25 preeclampsia; chronic liver failure, brain and spinal cord trauma, and cancer. The inflammatory disease can also be a systemic inflammation of the body, exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to proinflammatory cytokines, *e.g.*, shock associated with proinflammatory cytokines. Such shock can be induced, *e.g.*, by a chemotherapeutic agent
30 that is administered as a treatment for cancer. Other disorders include depression, obesity, allergic diseases, acute cardiovascular events, muscle wasting diseases, and cancer cachexia. Also inflammation that results from surgery and trauma can be treated with the concentrated therapeutic phospholipid compositions.

35

- 5 [0109] Also provided are methods for inhibiting, preventing, or treating
hypertriglyceridemia in subject. In some embodiments, the hypertriglyceridemia is moderate
hypertriglyceridemia. In some embodiments, the subject is diagnosed with moderate
hypertriglyceridemia. Moderate hypertriglyceridemia is defined as a subject having a TG
level of > 3.9 mmol/L (>350 mg/dL).
- 10 [0110] Also provided are methods for reducing fasting plasma levels of Low-density
Lipoprotein Cholesterol (LDL-C) in a subject. In some embodiments of reducing fasting
plasma levels of Low-density Lipoprotein Cholesterol (LDL-C), the subject is diagnosed with
moderate hypertriglyceridemia.
- 15 [0111] Also provided are methods for increasing fasting plasma levels of High-density
Lipoprotein Cholesterol (HDL-C) in a subject. In some embodiments of increasing fasting
plasma levels of High-density Lipoprotein Cholesterol (HDL-C), the subject is diagnosed
with moderate hypertriglyceridemia.
- 20 [0112] Also provided are methods for increasing the Omega-3 index (OM3I) in a
subject. The Omega-3 Index is defined as the percentage of EPA+DHA in red blood cells
(RBC) which can be represented by the formula: $OM3I = (EPA + DHA) / \text{Total fatty acids in RBC}$. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden
25 cardiac death and can be viewed as a marker of increased risk (an actual risk factor) for death
from coronary heart disease (Harris, 2010). In other embodiments, the method provided
elevates the omega-3 index (OM3I) and reduces oral glucose intolerance (OGTT). In some
embodiments of increasing omega-3 index, the subject is diagnosed with moderate
hypertriglyceridemia.
- 30 [0113] Also provided are methods for reducing high sensitivity C-reactive protein (hs-
CRP) in a subject. In some embodiments of reducing high sensitivity C-reactive protein (hs-
CRP), the subject is diagnosed with moderate hypertriglyceridemia.

35

5 [0114] Also provided are methods for inhibiting, preventing, or treating cardiovascular disease in a subject. Cardiovascular diseases include atherosclerosis, arteriosclerosis, coronary artery disease, heart valve disease, arrhythmia, heart failure, hypertension, orthostatic hypotension, shock, endocarditis, diseases of the aorta and its branches, disorders of the peripheral vascular system, and congenital heart disease.

10

[0115] Also provided are methods for inhibiting, preventing, or treating metabolic syndrome in a subject. Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes. It affects one in five people, and prevalence increases with age. Some studies estimate the prevalence in the USA to be up to 25% of the population. Metabolic syndrome is also known as metabolic syndrome X, syndrome X, insulin resistance syndrome, Reaven's syndrome, and CHAOS (Australia).

20 [0116] Also provided are methods for inhibiting, preventing, or treating a cognitive disorder, in a subject. The term "cognitive disease or disorder" as used herein should be understood to encompass any cognitive disease or disorder. Non-limiting examples of such a cognitive disease or disorder are Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), dyslexia, age-associated memory impairment and learning disorders, amnesia, mild cognitive impairment, cognitively impaired non-demented, pre-
25 Alzheimer's disease, autism, dystonias and Tourette syndrome, dementia, age related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, conditions that influence the intensity of brain waves and/or brain glucose utilization, stress, anxiety, concentration and attention impairment, mood deterioration, general cognitive and mental well being, neurodegenerative disorders,
30 hormonal disorders or any combinations thereof. In a specific embodiment, the cognitive disorder is memory impairment.

[0117] The term "improving a condition in a subject suffering from a cognitive disease or a cognitive disorder" as used herein should be understood to encompass: ameliorating
35 undesired symptoms associated with a disease, disorder, or pathological condition; preventing manifestation of symptoms before they occur; slowing down progression of a disease or disorder; slowing down deterioration of a disease or disorder; slowing down irreversible damage caused in a progressive (or chronic) stage of a disease or disorder; delaying onset of a

5 (progressive) disease or disorder; reducing severity of a disease or disorder; curing a disease or disorder; preventing a disease or disorder from occurring altogether (for example in an individual generally prone to the disease) or a combination of any of the above. For example, in a subject suffering from memory impairment, for example as a result of Alzheimer's Disease, symptoms including deterioration of spatial short-term memory, memory recall
10 and/or memory recognition are improved by use of a lipid concentrated therapeutic phospholipid composition.

[0118] Also provided are methods for inhibiting, preventing, or treating neurodegenerative disorder in a subject. Neurodegenerative disorder is defined as a chronic
15 progressive neuropathy characterized by selective and generally symmetrical loss of neurons in motor, sensory, or cognitive systems. Non limiting examples of neurodegenerative disorders include but are not limited to Alzheimer's disease, Pick's disease, Lewy body dementia Basal ganglia–Huntington's disease, Parkinson's disease, dentatorubropallidoluysian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia
20 Motor–amyotrophic lateral sclerosis, familial spastic paraparesis, spinal muscular atrophy, spinal and bulbar muscular atrophy, Lou Gehrig's disease, pre-dementia syndrome, Lewy body dementia, age-related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, dentatorubropallidoluysian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia,
25 amyotrophic lateral sclerosis, and familial spastic paraparesis.

[0119] Also provided are methods for reducing the decline of global cognitive function in a subject. In some embodiments, the reduction in decline of global cognitive function can be measured by the Neuropsychological Test Battery (NTB). In some embodiments, the subject
30 is diagnosed with early stage Alzheimer's disease.

[0120] Also provided are methods for reducing worsening of neuropsychiatric symptoms in a subject. In some embodiments, the reduction is measured by the Neuropsychiatric Inventory questionnaire (NPI). In some embodiments, the subject is diagnosed with early
35 stage Alzheimer's disease.

5 [0121] Also provided are methods for maintaining self-care and activities of daily living function in a subject suffering from Alzheimer's disease. In some embodiments, the subject is diagnosed with early stage Alzheimer's disease. In some embodiments, the maintaining self-care and activities of daily living function is measured by the Disability Assessment in Dementia caregiver-based interview (DAD).

10

[0122] Additional health disorders or conditions which may be treated or improved by the concentrated therapeutic phospholipid compositions include, but are not limited to, high blood cholesterol levels, high triglycerides levels, high blood fibrinogen levels, low HDL/LDL ratio, menopausal or post-menopausal conditions, hormone related disorders, vision disorders, immune disorders, liver diseases, chronic hepatitis, steatosis, lipid peroxidation, dysrhythmia of cell regeneration, destabilization of cell membranes, high blood pressure, cancer, hypertension, aging, kidney disease, skin diseases, edema, gastrointestinal diseases, peripheral vascular system diseases, allergies, airways diseases, and psychiatric diseases.

20

Combination Therapies

[0123] In some embodiments, the subject is administered an effective amount of a concentrated therapeutic phospholipid composition. In other embodiments, the treatment comprises a combination of a concentrated therapeutic phospholipid composition and treatment agents such as anti-dyslipidemic agents. Anti-dyslipidemic agents include but are not limited to atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

[0124] In other embodiments, the treatment comprises a combination of a concentrated therapeutic phospholipid composition and a cholinesterase inhibitor. Cholinesterase inhibitors include but are not limited to metrifonate (irreversible), carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demarcarium, rivastigmine, phenanthrene derivatives, galantamine, piperidines, donepezil, tacrine, edrophonium, huperzine A, ladostigil and ungeremine.

35

- 5 [0125] In some embodiments, the subject is administered a combination of a concentrated therapeutic phospholipid composition and at least one of vitamins, minerals, cox-inhibitors, sterols, fibrates, antihypertensives, insulin, cholesterol digestion inhibitors, for example, ezetimibe, fatty acids, omega-3 fatty acids, antioxidants, and the methylphenydate class of compounds, such as for example ritalin. In other embodiments, a combination of a
10 concentrated therapeutic phospholipid composition and elements depleted during traditional chronic treatments, such as for example during chronic treatment with statins. For example, in some embodiments, a concentrated therapeutic phospholipid composition is described which contains at least one of cox-2, folic acid, vitamin B6, vitamin B12, magnesium or zinc. In other embodiments, combination therapies comprising a concentrated therapeutic
15 phospholipid composition and potassium are described. Potassium is usually depleted during treatment with diuretics. Combination therapies reduce risk of side effects, increase benefits, increase solubility, and/or increase bioavailability.

Modes of Administration

- 20 [0126] Administration of the concentrated therapeutic phospholipid compositions can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, parenteral, transdermal, subcutaneous, or topical administration modes.

Pharmaceutical Formulations

- 25 [0127] Depending on the intended mode of administration, the compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
30 Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all using forms well known to those skilled in the pharmaceutical arts.

- [0128] Illustrative pharmaceutical compositions are tablets and gelatin capsules
35 comprising a concentrated therapeutic phospholipid composition neat, or if required, contains a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, lactose, dextrose, sucrose, mannitol, sorbitol,

- 5 cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, *e.g.*, silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also; c) a binder, *e.g.*, magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such
- 10 as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and/or polyvinylpyrrolidone, if desired; d) a disintegrant, *e.g.*, starches, agar, methyl cellulose, bentonite, xanthan gum, algiic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween™ 80, Labrasol™, HPMCT™, DOSS™, caproyl™ 909,
- 15 labrafac™, labrafil™, peccol™, transcuto™, capmul™ MCM, capmul™ PG-12, captex™ 355, gelucire™, vitamin E TGPS or other acceptable emulsifier; and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.

[0129] Liquid, particularly injectable, compositions can, for example, be prepared by

20 dissolution, dispersion, *etc.* For example, the concentrated therapeutic phospholipid composition is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension. Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the concentrated therapeutic phospholipid

25 composition.

[0130] Other illustrative topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of the concentrated therapeutic phospholipid composition ranges from about 0.1 % to about 15 %, w/w or w/v.

30 *Dosing*

[0131] The dosage regimen utilizing the concentrated therapeutic phospholipid compositions is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the condition to be treated;

35 the route of administration; the renal or hepatic function of the subject; and the particular concentrated therapeutic phospholipid composition employed. A physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

- 5 [0132] Effective dosage amounts of the present invention, when used for the indicated effects, range from about 20 mg to about 10000 mg of the concentrated therapeutic phospholipid composition per day. Dosages for *in vivo* or *in vitro* use can contain about 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, 5000, 7500 or 10000 mg of the concentrated therapeutic phospholipid composition. Effective blood plasma levels after
10 administration of the concentrated therapeutic phospholipid composition to a subject can range from about 0.002 mg to about 100 mg per kg of body weight per day. Appropriate dosages of the concentrated therapeutic phospholipid composition can be determined as set forth in L.S. Goodman, *et al.*, *The Pharmacological Basis of Therapeutics*, 201-26 (5th ed. 1975).
- 15 [0133] The concentrated therapeutic phospholipid compositions can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. To be administered in the form of a transdermal delivery system, the dosage administration can be continuous rather than intermittent throughout the dosage
20 regimen. In some embodiments, of combination therapy, the concentrated therapeutic phospholipid composition and the therapeutic agent can be administered simultaneously. In other embodiments, the concentrated therapeutic phospholipid composition and the therapeutic agent can be administered sequentially. In still other embodiments of combination therapy, the concentrated therapeutic phospholipid composition can be
25 administered daily and the therapeutic agent can be administered less than daily. In still other embodiments of combination therapy, the concentrated therapeutic phospholipid composition can be administered daily and the therapeutic agent can be administered more than once daily.

EXAMPLES

- 30 [0134] The disclosure is further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other
35 and equivalents thereof which may suggest themselves to those skilled in the art without departing from the scope of the appended claims.

5 **Concentrated Therapeutic Phospholipid Compositions**

[0135] The following non-limiting examples of therapeutic compositions serve to illustrate further embodiments of the concentrated therapeutic phospholipid composition. It is to be understood that any embodiments listed in the Examples section are embodiments of the concentrated therapeutic phospholipid composition and, as such, are suitable for use in the methods and compositions described above.

[0136] The following methods can be used to make the concentrated therapeutic phospholipid compositions (Figure 1A and 1B)

 Step 1:

15 [0137] Frozen krill is mechanically crushed and incubated with a solvent in a ratio of 9:1 acetone water for 60-90 minutes at 8°C to extract different proportions of the lipids (PL, TG and FFA) from the krill biomass. Lipids are subsequently separated from proteins and krill material by filtration under pressure (50-60 kpa). The solid phase is discarded. The soluble extract is evaporated by a continuous distillation column under vacuum to remove the solvent (acetone). The major part of the aqueous (water) fraction is separated from the lipid fraction by decantation and the remaining water removed by evaporation under vacuum and gentle heating. Those fractions are dosed, analyzed, and blended to constitute an intermediary krill oil product which is re-analyzed to achieve desired specifications $\pm 5\%$: EPA (15g/100g), DHA (9g/100g), total phospholipids (42g/100g) and astaxanthin's forms (125mg/100g).

25 Step 2:

[0138] 100.5g of received krill oil from step 1 was charged to a 300ml extraction vessel (ID = 0.68"). The extractor was sealed, pre-heated CO₂ at 55°C was introduced from the bottom, and the pressure in the extractor was maintained at 5,000 psi using a diaphragm CO₂ pump. The flow of CO₂ was continued in the upflow direction through the extractor and was expanded to atmospheric pressure through a pressure-reduction-valve (PRV) so that the dissolved material in the CO₂ precipitated and collected in the flask. The flow rate and volume of CO₂ exiting the flask was measured with a flowmeter and dry test meter (DTM). A total of 7200g of CO₂ was passed through the extractor (solvent to feed ratio, S/F = 72) and 34.1% of the charge was removed by the CO₂. The flow of about 25 Standard Liters/min of CO₂ was maintained during the course of the test and the total time of extraction was

- 5 about 160min. The extractor was isolated and the CO₂ was vented to atmosphere. The extractor was opened and the un-extracted material (raffinate-product) was removed from the vessel.

Step 3:

- [0139] SC CO₂ Extraction to produce 90+% OM3:PLs. 9.44g of oil was mixed with
10 inert packing and charged to the extractor. The procedure carried out similar to that described in step 2 except more aggressive extraction conditions were used with the pressure and temperature in the extractor maintained at 10,000 psi and 70°C. A total S/F ratio of 200 was used; therefore, about 1900g of CO₂ was flowed through the extractor. A flow rate of CO₂ of about 10 Standard Liters/min was maintained; therefore, the total run time for this test was
15 105min. A total of 56.3% of the charge was extracted from this oil during the course of the run. The extractor was isolated, the CO₂ vented to atmosphere, the vessel opened, and the resulting raffinate-product scraped off the inert packing. This un-extracted material analyzed to be 91% OM3:PLs.

Composition 1

47 % OM3:PL			
*Total lipids as FA _{TG}	g/100g oil	61.3	(100)
*Omega-3	g/100g oil	14.1	(22,5)
*EPA	g/100g oil	7.4	(11,6)
*DHA	g/100g oil	3.8	(6,1)
*DPA	g/100g oil	0.2	(0,3)
*Omega-6	g/100g oil	10.8	(18,3)
*Linoleic acid	g/100g oil	10.6	(18,0)
*Omega-9	g/100g oil	6.6	(11,6)
*Oleic acid	g/100g oil	6.1	(10,8)
*Sat. FA _{TG}	g/100g oil	21.4	(36,1)
*Monounsatur. FA _{TG}	g/100g oil	13.9	(23,1)
*Polyunsatur. _{TG}	g/100g oil	26.0	(40,7)
*EPA as FA _{TG}	g/100g oil	7.7	
*DHA as FA _{TG}	g/100g oil	3.9	
Water	%	0.8	
Color	-	Red orange	
Odor	-	Slightly rancid	
Total carotenoids	mg/100g oil	36.0	
Astaxanthine	mg/100g oil	65.3	
Astaxanthine	% diester	83.1	
	% monoester	16.9	
	% free	0.0	
Peroxide Index	mEq peroxide/kg	1.0	
p-Anisidine Index	-	2.0	
Iodine Index	gI ₂ /100g oil	101.1	
Saponification Index	mg KOH/g oil	214.1	
Indice acide	mg KOH/g oil	17.2	
Total fat	%		
Free fatty acid	% as oleic acid	5.2	
Triglycerides	%	36.5	
Viscosity	cP	1323.0	
ash	%	5.0	
Vitamin A	UI/g Oil	40.4	
Vitamin E	UI/g Oil	0.1	
Total phospholipids	g/100g oil	47.2	
Phospholipid profile	TLC	-	
	% LPC	3.7	
	% PC	53.6	
	% PS	24.7	
	% PE	16.4	
	% PA	1.7	
Molecular mass PL	g/mol	773.8	

5

Composition 2

53% OM3:PL		
Total lipids as fatty acids (FA) TG	g / 100 g oil	69.80
Total Omega-3	g / 100 g oil	31.30
C 20:5 (n=3) EPA	g / 100 g oil	13.90
C 22:6 (n=3) DHA	g / 100 g oil	10.10
C 22:5 (n=3) DPA	g / 100 g oil	0.40
Total Omega-6	g / 100 g oil	1.60
linoleic acid - LA	g / 100 g oil	1.30
Total Omega-9	g / 100 g oil	6.10
oleic acid - OA	g / 100 g oil	5.70
Saturated FA	g / 100 g oil	21.10
Monounsaturated FA	g / 100 g oil	14.50
Polyunsaturated FA	g / 100 g oil	34.20
EPA as FA	g / 100 g oil	14.40
DHA as FA	g / 100 g oil	10.50
PHOSPHOLIPID PROFILE		
total	g / 100 g oil	52.30
lysophosphatidyl choline - LPC	%	10.80
sphingomyeline - SM	%	0.10
phosphatidyl choline - PC	%	79.70
phosphatidyl serine - PS	%	
phosphatidyl inositol - PI	%	
phosphatidyl ethanolamine - PE	%	9.40
PA	%	0.00
CAROTENOIDS		
total	mg / 100 g oil	92.60
total astaxanthin - AST	mg / 100 g oil	161.60
AST diester		62.00
AST monoester		35.00
AST free		3.00

Composition 3

66% OM3:PL		
Total lipids as fatty acids (FA) TG	g / 100 g oil	74.2
Total Omega-3	g / 100 g oil	39.8
C 20:5 (n=3) EPA	g / 100 g oil	21.7
C 22:6 (n=3) DHA	g / 100 g oil	14.1
C 22:5 (n=3) DPA	g / 100 g oil	0.5
Total Omega-6	g / 100 g oil	1.7
linoleic acid - LA	g / 100 g oil	1.3
Total Omega-9	g / 100 g oil	5.8
oleic acid - OA	g / 100 g oil	5.1
Saturated FA	g / 100 g oil	18.0
Monounsaturated FA	g / 100 g oil	13.2
Polyunsaturated FA	g / 100 g oil	43.1
EPA as FA	g / 100 g oil	22.6
DHA as FA	g / 100 g oil	14.6
PHOSPHOLIPID PROFILE		
total	g / 100 g oil	66.2
lysophosphatidyl choline - LPC	%	10.7
phosphatidyl choline - PC	%	75.3
phosphatidyl ethanolamine - PE	%	11.8
other	%	2.2
CAROTENOIDS		
total	mg / 100 g oil	273.4
total astaxanthin - AST	mg / 100 g oil	466.8
AST diester	%	57.4
AST monoester	%	40.7
AST free	%	1.9

5

Composition 4

80% OM3:PL		
Total lipids as fatty acids (FA) TG	g / 100 g oil	68.35
Total Omega-3	g / 100 g oil	37.90
C 20:5 (n=3) EPA	g / 100 g oil	20.40
C 22:6 (n=3) DHA	g / 100 g oil	12.95
C 22:5 (n=3) DPA	g / 100 g oil	0.48
Total Omega-6	g / 100 g oil	1.45
linoleic acid - LA	g / 100 g oil	1.26
Total Omega-9	g / 100 g oil	4.93
oleic acid - OA	g / 100 g oil	4.35
Saturated FA	g / 100 g oil	16.15
Monounsaturated FA	g / 100 g oil	11.21
Polyunsaturated FA	g / 100 g oil	40.99
EPA as FA	g / 100 g oil	21.30
DHA as FA	g / 100 g oil	13.50
PHOSPHOLIPID PROFILE		
total	g / 100 g oil	80.00
lysophosphatidyl choline - LPC	%	9.20
sphingomyeline - SM	%	0.20
phosphatidyl choline - PC	%	80.60
phosphatidyl serine - PS	%	1.10
phosphatidyl inositol - PI	%	0.10
phosphatidyl ethanolamine - PE	%	7.50
PA	%	1.30
CAROTENOIDS		
total	mg / 100 g oil	180.4
total astaxanthin - AST	mg / 100 g oil	325.5
AST diester	%	68.45
AST monoester	%	29.27
AST free	%	2.28

Composition 5

90% OM3:PL		
*Total lipids as FA _{TG}	g/100g oil	63.9
*Omega-3	g/100g oil	35.1
*EPA	g/100g oil	18.9
*DHA	g/100g oil	12.2
*DPA	g/100g oil	0.5
*Omega-6	g/100g oil	1.3
*Linoleic acid	g/100g oil	1.2
*Omega-9	g/100g oil	4.6
*Oleic acid	g/100g oil	3.9
*Sat. FA _{TG}	g/100g oil	15.8
*Monounsat. FA _{TG}	g/100g oil	10.2
*Polyunsat. _{TG}	g/100g oil	37.9
*EPA as FA _{TG}	g/100g oil	19.7
*DHA as FA _{TG}	g/100g oil	12.7
Acetone	Ppm	1.6
Humidity and volatiles	%	1.7
Water	%	1.9
Color	-	Red chili
Odor	-	shellfish
Total carotenoids	mg/100g oil	168.9
Astaxanthine	mg/100g oil	309.3
Astaxanthine	% Diester	73.1
	% Monoester	25.3
	% Libre	1.6
Index p-Anisidine	-	3.1
Index acid	mg KOH/g oil	33.6
Index iodine	gI ₂ /100g oil	
Index saponification	mg KOH/g oil	
Index Peroxide	mEq peroxyde/kg	0.1
Vitamin A	UI/g Oil	15.2
Vitamin E	UI/g Oil	0.3
Fatty acid total	%	97.6
Viscosity	cP	
Total phospholipids	g/100g oil	90.6
Phospholipid profile	TLC	-
	% LPC	13.5
	% SM	0.4
	% PC	76.3
	% Autres PL	1.2
	% PE	7.9
	% PA	0.8
Triglycerides	%	0.0

Composition 6

70% OM3:PL derived from Squid		
*Total lipids as FA _{TG}	g/100g oil	54,5
*Omega-3	g/100g oil	29,1
*EPA	g/100g oil	8,9
*DHA	g/100g oil	18,3
*DPA	g/100g oil	0,2
*Omega-6	g/100g oil	0,7
*Linoleic acid	g/100g oil	0,3
*Omega-9	g/100g oil	4,2
*Oleic acid	g/100g oil	2,0
*Sat. FA _{TG}	g/100g oil	16,9
*Monounsatur. FA _{TG}	g/100g oil	6,8
*Polyunsatur. TG	g/100g oil	30,9
*EPA as FA _{TG}	g/100g oil	9,3
*DHA as FA _{TG}	g/100g oil	19,1
Humidity (calmar)	%	
Indice acide	mg KOH/g oil	55,7
Vitamin A	UI/g Oil	
Vitamin E	UI/g Oil	
Fatty acid total	%	2,7
Total carotenoids	mg/100g oil	8,3
Astaxanthine	mg/100g oil	13,2
Astaxanthine	% dicster	42,5
	% monoester	35,6
	% libre	21,9
Total phospholipids	g/100g oil	70,8*
Phospholipid profile	TLC	-
	% LPC	12,4
	% SM	7,8
	% PC	55,8
	% other	2,0
	% PE	22,0
	% PA	6,4
Triglycerides	%	25,0
Free fatty acid	% as oleic acid	3,2
Index p-Anisidine	-	4,3
Index Peroxide	mEq peroxyde/kg	0,6
**PM Phospholipids (g/mol)		847,14
<i>Profile of Fatty Acids of the PL</i>		
*Total lipids as FA	g/100g PL	53,9
*Oméga-3	g/100g PL	28,6
*EPA	g/100g PL	9,0
*DHA	g/100g PL	18,3
*DPA	g/100g PL	0,2
*Omega-6	g/100g PL	0,5
*Linoleic acid	g/100g PL	0,2
*Omega-9	g/100g PL	3,6

70% OM3:PL derived from Squid		
*Oleic acid	g/100g PL	1,5
*Sat. FA	g/100g PL	18,3
*Monounsat. FA	g/100g PL	5,4
*Polyunsat.FA	g/100g PL	30,2

5

Biological Examples

Example 1

Managing Dyslipidemia in Three Murine Phenotypes

[0140] The aim of this study was to examine the effects of Composition 3 in three age-
 10 /sex-matched murine phenotypes representative of (1) normal healthy non-obese
 normoglycemic control (C57BL6) versus (2) hyperdyslipidemic LDL-receptor gene knockout
 (LDLr -/-) or (3) human apoA-I transgenic mice (Jackson Labs) at 12-w of age: 27.5±0.7 vs
 25.6±0.7 vs 29.2±0.8 gr., respectively; n=7-10/gr. kept according to local and national ethic
 regulations, fed a normal vs a Western-diet regime and water *ad libitum*. Data are presented
 15 as mean±sem and statistics assessed by t- test (unpaired, two-tail) (v5-GraphPad Prism).

[0141] The profile of plasma lipids concentrations (mg/dL) in the above-three untreated
 adult male murine models were as reported in the literature: Total cholesterol (TC): 71.1±3.3
 vs 215.3±10.4 vs 50.3±1.3; triglycerides (TGs): 59.5±4.5 vs 65.1±3.8 vs 53.0±12.9; low-
 density lipoprotein (LDL): 13.3±1.2 vs 101.6±6.7 vs 12.2±1.6; high-density lipoprotein
 20 (HDL): 53.4±3.2 vs 88.8±3.6 vs 24.8±2.6. Six (6) weeks of QD treatment with Composition
 3 (104 vs 208 vs 417 mg/kg (Human equivalent dosing of 500, 1,000 and 2,000 mg/day) in
 C57BL6 led to significant dose-dependent decrease in plasma TGs (up to 60%), reduced LDL
 (up to 28%), elevated HDL (by 17%) but did not affect TC (see Figures 2-12 and Table 1).
 In severely dyslipidemic LDLr-KO mice, Composition 3 led to significant dose-dependent
 25 decrease in plasma TGs, elevated further HDL, caused a slight elevation in TC (only at mid-
 dose) and did not affect LDL (see Figures 13-17 and Table 1). In hApoA-I transgenic mice,
 Composition 3 led to significant decrease in plasma TGs, elevated HDL and did not affect TC
 (see Figure 18 and Table 1). The liver concentrations of TC were the same in all three
 phenotypes but TGs were reduced (19%; p<0.05) in LDLr-KO and elevated (153%; p<0.01)
 30 in hApoA-I, compared to control C57BL6. Treatment with Composition 3 elevated liver TC

- 5 and TGs by up to 12% and 27%, respectively, in C57BL6, by up to 10% and 36% in LDLr-KO and by up to 10% for TC but mixed effects for TGs (-13 to +12%) in hApoA-I mice, respectively (see Table 2).

Table 1: Effects mediated by 6-weeks treatment with Composition 3 on plasma lipids.

Murine phenotype	Plasma Lipids	Low dose 104 mg/kg (HED: 500mg/day)	Mid-dose 208 mg/kg (HED: 1000mg/day)	High-dose 417 mg/kg (HED: 2000mg/day)
C57BL6	TC	75.9±2.0 up 6.8% (NS)	80.6±3.3 up 13.4% (NS)	78.1±2.7 up 9.8% (NS)
	TGs	32.2±1.6 down 46% (p<0.001)	25.0±2.8 down 56% (p<0.001)	23.8±1.2 down 60% (p<0.001)
	LDL	11.1±1.4 down 15% (NS)	11.2±1.0 down 16% (p<0.05)	9.6±0.7 down 28% (p<0.05)
	HDL	59.4±1.9 up 11% (NS)	63.4±3.5 up 19% (NS)	62.3±2.4 up 17% (p<0.05)
LDLr-KO	TC	219.3±7.4 up 2% (NS)	244.4±7.9 up 14% (p<0.01)	238.5±6.9 up 11% (NS)
	TGs	45.7±2.8 down 30% (p<0.001)	41.7±4.9 down 36% (p<0.01)	36.7±1.6 down 44% (p<0.001)
	LDL	99.2±5.7 down 2% (NS)	116.2±4.4 up 14% (NS)	97.4±6.5 down 4% (NS)
	HDL	90.9±2.5 up 2% (NS)	88.4±4.6 = (NS)	111.2±2.5 up 25% (p<0.001)
hApoA-I transgenic	TC	51.1±1.5 up 2% (NS)	57.2±2.6 up 14% (p<0.05)	50.1±1.4 = (NS)
	TGs	19.3±2.8 down 64% (p<0.05)	43.2±11.7 down 18% (NS)	43.0±8.2 down 19% (NS)
	LDL	10.8±1.0 down 11% (NS)	12.8±2.3 = (NS)	13.9±1.0 up 14% (NS)
	HDL	27.9±2.4 up 13% (NS)	28.6±2.6 up 15% (NS)	21.6±12.8 down 13% (NS)

NS; not significant

10 **Table 2: Plasma lipids at baseline between murine phenotype**

Plasma concentrations (mg / dL)	C57BL6 control	LDLr-KO	Variation vs control	hApoA-I transgenic	Variation vs control
total cholesterol (TC)	71.1±3.3	215.3±10.4	up 3-fold p<0.001	50.3±1.3	down 29.3% NS
triglycerides (TGs)	59.5±4.5	65.1±3.8	up 9.4% NS	53.0±12.9	down 10.9% NS
low density lipoprotein (LDL-C)	13.3±1.2	101.6±6.7	up 7.6-fold p<0.001	12.2±1.6	down 8.3% NS
high-density lipoprotein (HDL-C)	53.4±3.2	88.8±3.6	up 166% p<0.001	24.8±2.6	down 54% p<0.001
Liver concentrations (µg / mg)					
total cholesterol (TC)	23.1±0.8	23.6±0.6	= (NS)	25.1±0.5	up 9% (NS)
triglycerides (TGs)	53.0±3.1	42.9±2.1	down 19% p<0.05	81.3±7.4	up 153% p<0.001

NS; not significant

5 [0142] These data indicate that the Composition 3 is an effective modulator of lipid metabolism, mainly at reducing plasma TGs and LDL and elevating HDL. These data indicate that in some embodiments, concentrated therapeutic phospholipid compositions can be effective as a therapy against moderate to severe hypertriglyceridemia. In some
10 embodiments, concentrated therapeutic phospholipid compositions in combination with other anti-dyslipidemic agents can be effective at lowering refractory hypertriglyceridemia.

Example 2

Increase of the circulating plasma concentration of high-density Lipoprotein-Cholesterol (HDL-C) and Reduced Total Cholesterol (TC) / HDL ratio in 12-week old Male Zucker Diabetic Fatty Rats.

15 [0143] The purpose of this study was to examine the effects of the concentrated therapeutic phospholipid compositions in the Zucker Diabetic Fatty rat rodent model for type 2 diabetes with obesity, hyperlipidaemia and insulin resistance (ZDF; Gmi-fa/fa) vs age-/sex-matched normal healthy non-obese normoglycemic lean control SD rat (from Charles River Labs; 12-
20 w, 359±17 vs 439±13 gr.; n=9-12/gr.). Lipid profile (total cholesterol (TC), tryglycerides (TGs), High-Density Lipoprotein-Cholesterol (HDL-C) and TC / HDL ratio were assessed before, 1 and 2 month after QD treatment with Composition 3 (52 versus 260 mg/kg (HED of 500 and 2,500 mg), and kept according to local and national ethic regulations (Formulab high fat 5008 (ZDF) vs normal 5001 (SD) diet regime and water *ad libitum*). Data are presented
25 as Mean±SD (n=2-10) and statistical differences calculated by unpaired two-tailed t test (v5-GraphPad Prism). At 12-w of age, the circulating plasma concentrations of TC, TGs, HDL and TC/HDL ratio were: 4.6±0.9, 11.6±5.9, 2.3±1.1 mmol / L and 2.16±0.62, respectively. Lipids' profile in SD rats were significantly lower at 1.9±0.4, 1.2±0.4, 1.3±0.2 mmol / L and 1.45±0.11, respectively. Daily low and high dose treatment for 60 days did not affect TC and
30 TGs concentrations but increased by 1.7- to 1.8-fold (p<0.01) "good" HDL-cholesterol and decreased the TC / HDL ratio by 26-32% (p<0.01-0.05), respectively.

5

Example 3**Improved Glucose Intolerance in Zucker Diabetic Fatty Rats after Administration of Composition 3**

[0144] The purpose of this study was to investigate the effects of Composition 3 in an overtly dislipidemic, obese, type 2 diabetic rat model. Zucker Diabetic Fatty (ZDF; Gmi-fa/fa) rats were used *versus* age-/sex-matched normal healthy non-obese normoglycemic lean control SD rat (from Charles River Labs; 12-w, 359±17 vs. 439±13 gr.; n=9-12/gr.). Glucose intolerance was assessed conducting an oral glucose tolerance test (OGTT; overnight fasting then single gavage of glucose 2 g/kg rat b.w.) over 180 minutes using glucometer strips (Accu-Chek Aviva, Roche Diagnostics), before and 90 days after treatment with Composition 3 given by QD gavage at 52 versus 260 mg/kg (HED of 500 and 2,500 mg), and kept according to local and national ethic regulations (Formulab high fat 5008 (ZDF) vs normal 5001 (SD) diet regime and water *ad libitum*). Data are presented as Mean±SD and statistical differences calculated by unpaired two-tailed t test (v5-GraphPad Prism).

[0145] At 12-w of age (T_0) fasting circulating plasma concentrations of glucose were 7.8±2.1 vs 5.0 ± 0.6 mmol/L ($p<0.001$) in untreated ZDF vs SD rats. Non-fasting ZDF and SD rats glucose levels were 22.0±4.2 vs 8.6±0.6 mmol / L, respectively. One month later, baseline values increased by 1.9-fold ($p<0.0001$) in fasted ZDF while remaining unchanged in fasted SD. Aging did not affect glucose levels in non-fasted rats. Glucose challenge led to a maximum 2.5-fold ($p<0.0001$) and 1.6-fold ($p<0.0001$) increase in plasma glucose concentrations in untreated fasted ZDF and SD, at 30 and 60 minutes, respectively, returning mostly to initial values after 180 mins. At 16 weeks of age, thirty days (T_{30}) of treatment did not affect either the profile (AUC) or maximum elevation in glucose in SD rats but treatment of ZDF shifted to the right the maximum elevation in plasma glucose (from 30 to 60 minutes), reduced by 61-72% ($p<0.02$) the peak elevation at 30 minutes and reduced by 50-60% ($p<0.0001$) the AUC at either doses of Composition 3, thus back to the AUC observed in untreated glucose challenged SD rats. At 20 weeks of age, 60 days of treatment, either dosing did not further attenuate glucose intolerance. None of the treatment profile affected the plasma and urinary concentrations of glucose (hyperglycemia and glucosuria) in non-fasted ZDF or SD. These data indicate that a short term and low dose chronic administration of Composition 3 significantly improves glycemic control in a model of severe hyperglycemia.

5 **Example 4**

A randomized, placebo-controlled, double-blind, dose-ranging and multi-centered trial to evaluate the safety and efficacy of concentrated therapeutic phospholipid compositions in the treatment of moderate hypertriglyceridemia.

- 10 Subjects with moderate hypertriglyceridemia treated by physician according to the Canadian Lipid Treatment Guidelines who are treated over 12 weeks with concentrated phospholipid given at doses of 1.0, 2.0 or 4.0g. The primary measure of efficacy will be the percent change in fasting blood circulating serum triglycerides (TGs) between baseline (Week 1) and 12 weeks of treatment. Secondary Outcomes: between baseline and after six weeks and 12
- 15 weeks of treatment: 1) absolute change in fasting plasma TGs; 2) percentage (%) of subjects achieving target TG fasting plasma levels; 3) absolute change in fasting plasma LDL-C, VLDL-C, HDL-C, HDL2-C, HDL3-C, Total Cholesterol, hs-CRP and non-HDL; 4) percentage (%) change in fasting plasma concentrations of LDL-C, VLDL-C, HDL-C, HDL2-C, HDL3-C, TC, hs-CRP and non-HDL; 5) calculated Ratios: a) total cholesterol :
- 20 HDL-C; b) LDL-C : HDL-C; c) TGs : HDL-C; 6) LDL-C-related parameters: a) particle number; b) particle size; c) oxidation; 7) absolute and percent (%) change in fasting plasma concentrations of biomarkers; a) glycated Hemoglobin (HbA1c), b) apolipoprotein A-I (ApoA-I), c) apolipoprotein B-100 (ApoB-100), d) apolipoprotein E (ApoE), e) lipoprotein(a) (Lp(a)), f) adiponectin, g) glucose, h) insulin; 8) calculated ApoB : ApoA-I ratio; 9) fasting
- 25 plasma lipoprotein-associated phospholipase A2 activity (Lp-PLA2); 10) HOMA-IR (homeostasis model assessment of insulin resistance: [glucose (mmol / L) x IRI (microIU / L) / 22.5]; 11) plasma concentrations of total EPA and DHA (PK/PD – 25 subjects/group); 12) OM3I (Omega-3 index); 13) Subjects Genetic Polymorphism: a) Lecithin:Cholesterol Acyltransferase (LCAT), b) cholesteryl ester transfer protein (CETP), c) scavenger receptor
- 30 type B-1 (SR-B1), d) ATP Binding Cassette transporter 1 (ABCA1).

5 **Example 5**

Preclinical non-GLP assessment of efficacy of concentrated therapeutic phospholipid compositions alone or in combination with a statin on modulating blood lipids and the development of atherosclerotic lesions in ApoE null mice fed a Western-type diet.

10 Male adult mice (n=135 (15 mice / group) 5-6 weeks of age) weighing about 18-20g each homozygous for the Apoetm1Unc mutation are administered HOW either Vehicle (Water or 0.2%-0.5% Carboxymethylcellulose); composition 3 (1,000 mg/daily HED); composition 3 (2,000 mg/daily HED); or Lipitor (20 mg/daily HED); or composition 3 (1,000 mg/daily HED) + Lipitor (20 mg/daily HED). At 0, 3 months, or 6 months the following assessment
15 of values is made relative to: blood Lipids: TC, TGs, LDL, HDL, non-HDL, VLDL (0, 3 and 6 months) (2)Aortic Atherosclerosis (0, 3 and 6 months): a. Thoracic and abdominal aorta will be isolated, trimmed of fat, laid out and pinned on black matrix for photography, and stained with Sudan IV or Oil Red-O. b.Vessel will be imaged for surface involvement using a
20 computerized image analysis system (Image ProPlus or NIH Package Software). The data will be computed by group and statistically analyzed. c.Lipid extraction: Following staining and morphometric analysis, aortas will be extracted (Bligh/Dyer). (3) Red blood cells Omega-3 Index (0, 3 and 6 months); (4) Circulating plasma concentration of CRP (0, 3 and 6 months).

25 **Example 6**

Comparison of Composition 3 with Lovaza® on the Omega 3 Index

Male sdult (14 weeks) Sprague-Dawley (SD) rats with an average body weight of >375-425 were fed normal rat chow(diet 5075- normal, standard rat chow). Number of test subjects / group: n=56; n=8 rats / gr. Dosing was QD (single daily dosing/morning) for 12 weeks with
30 either (i) Vehicle (ii) Composition 3 52 mpk 500 mg / day HED; (iii) Composition 3 104 mpk 1000 mg / day HED; (iv) Composition 3 416 mpk 4000 mg / day HED; (v) Lovaza® 416 mpk = 4000 mg / day HED. Results are shown in Figure 35.

5

Example 7**Monotherapy study of Concentrated Phospholipids in early stage Alzheimer's Disease**


Subjects will be randomly assigned to receive either concentrated therapeutic phospholipid composition 1 g, fish oil (135 mg EPA: 108 mg DHA) 1 g, or placebo (soy oil) 1 g once daily. The primary outcome measure will be the change in NTB between baseline and 24 weeks of treatment. The Neuropsychological Test Battery (NTB) will be used to monitor and evaluate important cognitive changes. The following 9 components of the NTB are used to determine the outcome for the subject: (1) Wechsler Memory Scale, visual immediate (score range, 0-18), (2) Wechsler Memory Scale verbal immediate (score range, 0-24), (3) Rey Auditory Verbal Learning, Test (RAVLT) immediate (score range, 0-105), (4) Wechsler, Memory Digit Span (score range, 0-24), (5) Controlled Word Association, Test (COWAT), (6) Category Fluency Test (CFT), (7) Wechsler, Memory Scale visual delayed (score range, 0-6), (8) Wechsler, Memory Scale verbal delayed (score range, 0-8), and (9) RAVLT, delayed (score range, 0-30) (Harrison et al. 2007). The RAVLT delayed measure is composed of delayed recall and recognition performance components that are summed to yield a score ranging from 0 to 30, yielding 9 measures of subject performance. Secondary outcome measures will include the change in the NPI and DAD at 24 weeks of treatment. The NPI evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behaviour, night-time behaviour disturbances, and appetite and eating abnormalities. The DAD is a caregiver-based interview instrument used to evaluate instrumental and basic activities of daily living in dementia (hygiene, dressing, undressing, continence, eating, meal preparation, telephoning, going on an outing, finance, correspondence, medication, leisure and housework). The NPI also assesses the amount of caregiver distress engendered by each of the neuropsychiatric disorders. Blood is drawn and levels of EPA, DHA and phospholipids is measured.

EQUIVALENTS

[0146] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.


CLAIMS

1. A concentrated therapeutic phospholipid composition comprising
-compounds of the Formula I:



wherein R_1 and R_2 each independently represent a docosahexaenoic acid (DHA) or an eicosapentaenoic acid (EPA) residue; and

wherein each X is independently selected from $-\text{CH}_2\text{CH}_2\text{NH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ and



-free EPA and free DHA, wherein the total free and bound EPA in the extract is at a concentration of between 15% and 25% (w/w), and the total free and bound DHA in the extract is at a concentration of between 10% and 15% (w/w),

wherein the total phospholipids in the composition are at a concentration of 50% (w/w (phospholipids/composition)) to $55\% \pm 5\%$ (w/w (phospholipids/composition)).

2. The composition of claim 1, wherein the total phospholipids in the composition are at a concentration of 55% (w/w (phospholipids/total composition)).
3. The composition of claim 1 or 2, further comprising an antioxidant.
4. The composition of claim 3, wherein the antioxidant is selected from astaxanthin, a carotenoid, vitamin A and vitamin E.

5. The composition of claim 4, wherein the antioxidant is vitamin E.
6. The composition of claim 4, wherein the antioxidant is astaxanthin.
7. The composition of any one of claims 1-6, wherein the composition further comprises triglycerides in a concentration of below about 5% (w/w).
8. The composition of any one of claims 1-7, wherein the composition comprises an extract derived from a marine source.
9. The composition of claim 8, wherein the extract is derived from krill.
10. The composition of any one of claims 1-9, said composition formulated as a capsule.
11. Use of the composition of any one of claims 1-10 for treating or preventing a cardiometabolic disorder / metabolic syndrome.
12. Use of the composition of any one of claims 1-10 in the manufacture of a medicament for treating or preventing a cardiometabolic disorder / metabolic syndrome.
13. The use of claim 11 or 12, wherein the cardiometabolic disorder / metabolic syndrome is selected from atherosclerosis, dyslipidemia, hypertriglyceridemia, hypertension, heart failure, cardiac arrhythmias, low HDL levels, high LDL levels, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis, type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolemia, stroke, hyperlipidemia, hyperlipoproteinemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, omega-3 deficiency, phospholipid deficiency, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, acute coronary syndrome (ACS), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), arterial occlusive diseases, cerebral atherosclerosis, arteriosclerosis, cerebrovascular disorders, myocardial ischemia, coagulopathies leading to thrombus formation in a vessel and diabetic autonomic neuropathy.

14. Use of the composition of any one of claims 1-10 for treating, preventing, or improving cognition and /or a cognitive disease, disorder or impairment.

15. Use of the composition of any one of claims 1-10 in the manufacture of a medicament for treating, preventing, or improving cognition and /or a cognitive disease, disorder or impairment.

16. The use of claim 14 or 15, wherein the cognitive disease, disorder or impairment is selected from Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), dyslexia, age-associated memory impairment and learning disorders, amnesia, mild cognitive impairment, cognitively impaired non-demented, pre-Alzheimer's disease, autism, dystonias and Tourette syndrome, dementia, age related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, conditions that influence the intensity of brain waves and/or brain glucose utilization, stress, anxiety, concentration and attention impairment, mood deterioration, general cognitive and mental well-being, neurodegenerative disorders, hormonal disorders and any combinations thereof.


17. Use of the composition of any one of claims 1-10 for inhibiting, preventing, or treating a neurodegenerative disorder.

18. Use of the composition of any one of claims 1-10 in the manufacture of a medicament for inhibiting, preventing, or treating a neurodegenerative disorder.

19. The use of claim 17 or 18, wherein the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, Lewy body dementia Basal ganglia-Huntington's disease, Parkinson's disease, dentatorubropallidoluysian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia Motor-amyotrophic lateral sclerosis, familial spastic paraparesis, spinal muscular atrophy, spinal and bulbar muscular atrophy, Lou Gehrig's disease, pre-dementia syndrome, Lewy body dementia, age-related cognitive decline, cognitive deterioration, moderate mental impairment, mental deterioration as a result of ageing, dentatorubropallidoluysian atrophy, Freidreich's ataxia, multiple system atrophy, types 1, 2, 3, 6, 7 spinocerebellar ataxia, amyotrophic lateral sclerosis, and familial spastic paraparesis.


20. Use of the composition of any one of claims 1-10 for the treatment of cardiovascular diseases.

21. Use of the composition of any one of claims 1-10 in the manufacture of a medicament for the treatment of cardiovascular diseases.
22. The use of claim 20 or 21, wherein the composition reduces triglycerides, reduces LDL cholesterol, and increases HDL cholesterol.
23. Use of the composition of any one of claims 1-10 for the treatment of hypertriglyceridemia.
24. Use of the composition of any one of claims 1-10 in the manufacture of a medicament for the treatment of hypertriglyceridemia.
25. The use of claim 23 or 24, wherein said composition reduces triglycerides, reduces LDL cholesterol, and increases HDL cholesterol.
26. A concentrated therapeutic phospholipid composition for reducing triglycerides level comprising compounds of the Formula I:



wherein R_1 and R_2 each independently represent a docosahexaenoic acid (DHA) or an eicosapentaenoic acid (EPA) residue; and

each X is independently selected from $-\text{CH}_2\text{CH}_2\text{NH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$ and



wherein the total phospholipids in the composition are at a concentration of 50% (w/w (phospholipids/composition)) to 55% $\pm$ 5% (w/w (phospholipids/composition)).

27. The composition of claim 26, wherein the total phospholipids in the composition are at a concentration of 55% (w/w (phospholipids/total composition)).

28. The composition of claim 26 or 27, further comprising an antioxidant.

29. The composition of claim 28, wherein the antioxidant is selected from astaxanthin, a carotenoid, vitamin A and vitamin E.

30. The composition of claim 28, wherein the antioxidant is vitamin E.

31. The composition of claim 28, wherein the antioxidant is astaxanthin.

32. The composition of any one of claims 26-31, wherein the composition further comprises free EPA and free DHA.

33. The composition of claim 32, wherein the total free and bound EPA in the extract is at a concentration of between 15% and 25% (w/w).

34. The composition of claim 32 or 33, wherein the total free and bound DHA in the extract is at a concentration of between 10% and 15% (w/w).

35. The composition of any one of claims 26-34, wherein the composition further comprises triglycerides in a concentration of below about 5% (w/w).

36. The composition of any one of claims 26-35, wherein the composition comprises an extract derived from a marine source.

37. The composition of claim 35, wherein the extract is derived from krill.

38. The composition of any one of claims 26-36, said composition formulated as a capsule.




FIGURE 1A




FIGURE 1B

3/37




FIGURE 1C

Circulating plasma Triglyceride concentration of C57BL/6 mice




FIGURE 2

Circulating plasma HDL-Cholesterol concentration of C57BL/6 mice

Mean	53.4	59.4	63.4	62.3
SEM	3.2	1.9	3.5	2.4
n	10	10	10	10




FIGURE 3

Circulating plasma *percentage* of HDL-Cholesterol in C57BL/6 mice

6/37

Mean	74.9	78.4	78.4	80.6
SEM	2.1	2.2	1.7	0.6
n	10	10	10	9


* $P < 0.05$

FIGURE 4

Circulating plasma LDL-Cholesterol concentration of C57BL/6 mice

Mean	13.3	11.1	11.2	9.6
SEM	1.2	1.4	1.0	0.7
n	10	10	10	9





FIGURE 5

Circulating plasma *percentage* of LDL-Cholesterol in C57BL/6 mice

Mean	18.9	14.5	14.1	12.2
SEM	1.8	1.7	1.4	0.5
n	10	10	10	9




* $P < 0.05$; ** $P < 0.01$

FIGURE 6

Circulating plasma NEFA concentration of C57BL/6 mice

Mean	2.92	2.65	2.93	2.63
SEM	0.10	0.06	0.12	0.09
n	10	9	9	9



* $P < 0.05$

FIGURE 7

10/37

Circulating plasma Glucose concentration of C57BL/6 mice

Mean	177.0	107.0	167.6	157.3
SEM	8.4	6.3	5.9	12.0
n	10	10	9	10


*** $P < 0.001$

FIGURE 8

Circulating plasma Phospholipid concentration of C57BL/6 mice

Mean	141.9	140.5	147.4	138.6
SEM	7.2	4.1	5.5	5.4
n	10	10	9	10




FIGURE 9

12/37

Circulating plasma ALT concentration of C57BL/6 mice

Mean	36.1	31.0	26.9	27.8
SEM	3.9	3.5	1.8	1.2
n	10	10	10	10





FIGURE 10

Liver Total Cholesterol concentration of C57BL/6 mice

Mean	23.1	23.3	25.8	24.1
SEM	0.8	0.6	0.3	0.8
n	10	10	9	10




** $P < 0.01$

FIGURE 11

Liver Triglyceride concentration of C57BL/6 mice

Mean	53.0	58.0	67.4	66.3
SEM	3.1	1.7	2.6	5.4
n	10	10	9	10




* $P < 0.05$; ** $P < 0.01$

FIGURE 12

Circulating plasma Triglyceride concentration of LDLr KO mice

Mean	65.1	45.7	41.7	36.7
SEM	3.8	2.8	4.9	1.6
n	9	10	10	10
		***	**	***




** $P < 0.01$; *** $P < 0.001$

FIGURE 13

Circulating plasma HDL-Cholesterol concentration of LDLr KO mice

Mean	88.8	90.9	88.4	111.2
SEM	3.6	2.5	4.6	2.5
n	9	9	9	10




***P<0.001

FIGURE 14

Circulating plasma *percentage* of HDL-Cholesterol in LDLr KO mice

Mean	43.0	41.9	35.1	46.8
SEM	2.1	0.8	2.3	1.1
n	10	9	10	10



* $P < 0.05$

FIGURE 15

18/37

Liver Total Cholesterol concentration of LDLr KO mice

Mean	23.6	24.5	25.8	24.9
SEM	0.6	0.3	0.9	0.6
n	10	9	10	10





FIGURE 16

Liver Triglyceride concentration of LDLr KO mice




* $P < 0.05$; ** $P < 0.01$

FIGURE 17

20/37

**Circulating plasma Triglyceride concentration of ApoA-1 CETP
Tg mice**

Mean	53.0	19.3	43.2	43.0
SEM	12.9	2.8	11.7	8.2
n	9	9	9	8
	—————*			



* $P < 0.05$

FIGURE 18

**Circulating plasma total cholesterol concentration of adult male SD,
ZDF, SHR & JCR:LA rats**





FIGURE 19

22/37


**Circulating plasma LDL/HDL concentration of adult male SD,
ZDF, SHR & JCR:LA rats**



#, 1 value removed

FIGURE 20

Circulating plasma HDL/LDL concentration of adult male SD, ZDF, SHR & JCR:LA rats




#, 1 value removed

FIGURE 21

24/37

**Circulating plasma total cholesterol/HDL concentration of adult male SD,
ZDF, SHR & JCR:LA rats**



#, 1 value removed

†, 2 values removed

FIGURE 22

25/37

Prothrombin Time of adult male SD, ZDF, SHR & JCR:LA rats





FIGURE 23

**OGTT area under the curve data in ZDF male rats treated with
Composition 3 for 90 days**




* $P < 0.05$; ** $P < 0.01$

FIGURE 24

27/37

OGTT area under the curve data in ZDF male rats treated with
Composition 3 for 90 days



* $P < 0.05$; ** $P < 0.01$

FIGURE 25

**OGTT area under the curve data in SD male rats treated with
Composition 3 for 90 days**

Mean	63.1	52.5	51.1	50.7	63.1	86.5	65.9	66.6
SEM	8.0	7.8	6.0	5.9	8.0	21.8	7.5	7.7
n	12	6	6	6	12	6	6	6




FIGURE 26

**OGTT area under the curve data in SD male rats treated with
Composition 3 for 90 days**




FIGURE 27

30/37

Effects of Composition 3 on lipid biomarkers in male ZDF rats compared to age-matched controls




FIGURE 28

Effects of Composition 3 on lipid biomarkers in male ZDF rats compared to age-matched controls




FIGURE 29

Effects of Composition 3 on lipid biomarkers in male ZDF rats compared to age-matched controls




FIGURE 30

33/37

Effects of Composition 3 on Glucose Intolerance in male ZDF rats




FIGURE 31

Effects of Composition 3 on Glucose Intolerance in male ZDF rats




FIGURE 32

35/37

Effects of Composition 3 on Glucose Intolerance in male SD rats




FIGURE 33

Effects of Composition 3 on Glucose Intolerance in male SD rats





FIGURE 34

37/37

Comparative Effects of Composition 3 and Lovaza® on Omega-3 Index



	Δ OM3I/G OM3	Δ OM3I/G EPA	Δ OM3I/G DHA
Comp. 3 1g	62.85%	103.26%	160.62%
Lovaza 4g	30.65%	55.37%	68.65%
Δ Comp. 3 vs Lovaza	105.70%	86.49%	133.95%

FIGURE 35